The Thermo Scientific Orbitrap Exploris MX enables customer success by combining high-quality data with operational simplicity
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
